Recombinant Human B7-H3(CD276) / His Protein
                            
                                
                                    
                                    
                                    
                                    
                                    
                                        - 价格: ¥2400/支
- 发布日期: 2024-02-01
- 更新日期: 2025-10-31
 
                             
                            
                         
                        
                     
                    
                 
             
            产品详请
            
                
                    
                    
                        | 产地 | China | 
                    
                        | 品牌 | Chemstan | 
                    
                        | 货号 | B21843201 | 
                    
                        | 用途 | Research Grade | 
                    
                        | 包装规格 | 200 ug | 
                    
                        | 纯度 | 95% | 
                    
                        | CAS编号 |  | 
                    
                        | 是否进口 | 是 | 
                    
                
             
            
                1.Alternative Name:4Ig-B7-H3,CD276
2.Target:B7-H3
3.Source:Human B7-H3 was expressed from HEK293 with poly His at the C-terminal
4.Sequence:Met1-Thr461
5.Protein structure:Q5ZPR3His
6.Molecular Characterization:The protein has a calculated MW of 48kDa.The reducing (R) heterodimer protein migrates as 70-100 kDa due to glycosylation
7.Purity:SDS-PAGE>95%,SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .
11.SDS-PAGE
	Determined by SDS-PAGE, the purity of the protein is greater than 95%.
12.SEC-HPLC
	Determined by SEC-HPLC, the purity of the protein is greater than 95%.
	13.ELISA
	
	
		When Recombinant Human B7-H3(CD276) / His Protein is immobilized at 5μg/mL (100 μL/well), the concentration of Anti-Human CD276 (Enoblituzumab) that produces 50% of the optimal binding response is approximately 20 ng/ml.